Sarepta shares plunge on U.K. trial halt, but analyst downplays safety fears
February 09, 2018 at 10:24 AM EST
The Cambridge biotech said a Duchenne muscular dystrophy patient had suffered a serious medical issue that was "possibly" related to the late-stage study.
